Prof Hoyle

Prof Hoyle

Prof Martin Hoyle
Professor of Health Innovation and Evaluation

Contact Details
Phone: +612 9850 6021
Email: Martin.Hoyle@mq.edu.au
Address: Suite 3-4, Level 1, EMC2 Building
3 Innovation Road, Macquarie Park, NSW, 2109

Research Interests
Health technology assessment
Economic evaluation methodology
NICE submissions

Biography

Prof Martin Hoyle is a Professor of Health Innovation and Evaluation at the Macquarie University Centre for the Health Economy (MUCHE).

Prof Hoyle has evaluated drugs in several clinical areas including various cancers (chronic lymphocytic leukaemia, chronic myeloid leukaemia, multiple myeloma, neuroendocrine tumours, colorectal cancer, gastro-intestinal stromal tumours, renal cell carcinoma, soft tissue sarcoma), chemotherapy-induced anaemia, multiple sclerosis, Alzheimer's disease. Other evaluations include cochlear implants for hearing, diagnostic tests for Lynch Syndrome and tests for pre-term labour in women. He has defended Assessment Group reports at 34 NICE Appraisal Committee meetings.

He has published papers on HTA methodology, specifically on assumptions regarding appropriate patient cohorts to model, assumptions for future drug prices and a method to recreate and analyse individual patient data using only summary survival data.

He was the external examiner for the MSc in Health Economics and Decision Modelling, University of Sheffield, from 2016 to 2018, and was a panel member for the Research for Patient Benefit (RfPB) South West. He was also an advisor to NICE on implementation of the NICE Fast Track Appraisal (FTA) process, and an advisor to NICE on implementation of the "Adjusted TA" process.

Prior to joining the Centre, Martin was Director of PenTAG (Peninsula Technology Assessment Group) in the Medical School at the University of Exeter, where he performed heath technology assessments for the National Institute for Health and Care Excellence (NICE), and the National Institute for Health Research (NIHR) in the United Kingdom. His undergraduate training was in Mathematics at the University of Cambridge.  This accounts for his interest in the mathematics and statistics of HTA.

Journal articles / reports

  • Snowsill T, Jones-Hughes, T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica Mota R, Peters J, Varley- Campbell J, Huxley N, Moore J, Allwood M, Lowe J, Hyde C, Hoyle M., Bond M, Anderson R Immunosuppressive agents in adult kidney transplantation in the NHS: a model-based economic evaluation,Nephrology Dialysis Transplantation, in press.
  • Tikhonova I, Hoyle M., Snowsill T, Cooper C, Varley-Campbell J, Rudin C, Mujica Mota R. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. (2016) PharmacoEconomics, doi:10.1007/s40273-016-0453-5.
  • Snowsill T, Huxley N, Hoyle M., Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C. (2015) “A model based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients”, BMC Cancer, 2015, 15:313.
  • Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M., Iqbal S, Van Cutsem E. (2013) “Mean Overall Survival Gain with Aflibercept Plus FOLFIRI versus Placebo Plus FOLFIRI in Patients with Previously Treated Metastatic Colorectal Cancer”, British Journal of Cancer, 1–9.
  • Ciani, O, Hoyle, M., Pavey, T., Cooper, C., Garside, R., Rudin, C., Taylor, R. (2013) “Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case-study for technology appraisal on the basis of surrogate outcomes evidence”, Value in Health, 16(6), 1081-1090.
  • Peters, J., Anderson, R., Hoyle, M., Hyde, C. (2013) "Evolution of a cost-utility model of donepezil for Alzheimer's disease", IJTAHC, 29(2):147-154.
  • Hoyle, M., Peters, J., Crathorne, L., Jones-Hughes, T., Cooper, C., Napier, M., Hyde, C. “Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for 3rd- and further lines of treatment for KRAS wildtype patients with metastatic colorectal cancer”, Value in Health, 2013, 16, 288-296.
  • Hyde, C., Bond, M., Peters, J., Rogers, G., Hoyle, M., Anderson, A., Jeffreys, M., Davis, S., Miners, A., Thokala, P., Wailoo, A, Moxham, T. (2013) “Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: systematic review and economic model.” Age & Ageing, 42:14-20.
  • Hoyle, M., Rogers, G., Moxham, T., Liu, Z., Stein, K. (2011) “Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or –intolerant chronic phase chronic myeloid leukaemia”, Value in Health, 14, 1057 – 1067.
  • Hoyle & Henley (2011) “Improved curve fits to summary survival data: application to economic evaluation of health technologies”, BMC Medical Research Methodology, 11:139:
  • Hoyle, M. (2011) “Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis”, PharmacoEconomics, 29(1): 1-15.
  • Hoyle, M. (2010) “Historical lifetimes of drugs in England: Application to value of information and cost effectiveness analyses”, Value in Health, 13(8); 885-892.
  • Hoyle, M. & Anderson, R. (2010) “Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts.” Medical Decision Making, 30: 426-437.
  • Hoyle, M., Green, C., Thompson-Coon, J., Liu, Z., Welch, K., Moxham, T., Stein K. (2010) “Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma”, Value in Health, 13(1), 55-60.
  • Hoyle, M., Green, C., Thompson-Coon, J., Liu, Z., Welch, K., Moxham, T., Stein K. (2010) “Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma” Value in Health, 13(1), 61-68.
  • Thompson-Coon, J., Liu, Z., Hoyle, M., Rogers, G., Green, C., Moxham, T., Welch, K., Stein K. (2009) “Sunitinib and bevacizumab for first line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness” British Journal of Cancer, 101; 238-43.
  • Hoyle, M. (2008) “Future drug prices and cost-effectiveness analyses”, PharmacoEconomics, 26(7), 589-602

NICE HTA

  • Jones-Hughes T., Dunham J., Robinson S., Napier M., Hoyle M. (2017) “Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours: A Single Technology Appraisal.”
  • Tikhonova I., Jones-Hughes T., Dunham J., Warren F., Robinson S., Stephens P., Hoyle M. (2017) “Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma: A Single Technology Appraisal.”
  • Varlet-Campbell J., Mujica-Mota R., Tikhonova I., Cooper C., Griffin E., Haasova M., Peters J., Lucherini S., Talens- Bou J., Long L., Sherriff D., Napier M., Ramage J., Hoyle M. (2016) “Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression.”
  • Huxley M, Long L, Briscoe S, Hoyle M. (2016) “The clinical and cost-effectiveness of lenalidomide for people who have received at least one prior therapy with bortezomib (partial review of TA171) A critique of the submission from Celgene: Addendum”
  • Mujica Mota R., Varley-Campbell J., Tikhonova I., Cooper C., Hoyle M., Rudin C, Rule S, Snowsill T (2016) “Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: A Single Technology Appraisal”
  • Huxley M., Crathorne L., Varley-Campbell J., Tikhonova I., Snowsill T., Briscoe S., Peters J., Bond M., Napier M., Hoyle M. (2015) “Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer”
  • Jones-Hughes T., Snowsill T., Haasova M., Coelho H., Crathorne L., Cooper C., Mujica-Mota R., Peters J., Varley- Campbell J., Huxley N., Moore J., Allwood M., Lowe J., Hyde C., Hoyle M., Bond M., Anderson R. (2015) “Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85).
  • Hoyle M., Huxley, N., Coelho. H., Lowe, J., Cooper, C., Crathorne, L., Peters, J, Rudin, C. (2014) “Ofatumumab in combination with chlorambucil or bendamustine for previously untreated chronic lymphocytic leukaemia: a critique of the submission from GSK. STA for NICE”.
  • Hoyle M., Long, L., Huxley, N., Crathorne, L., Briscoe, S., Rudin, C. (2014) “Obinutuzumab in combination with chlorambucil for previously untreated chronic lymphocytic leukaemia: a critique of the submission from Roche”.
  • Crathorne, L., Huxley, N., Haasova, M., Snowsill, T., Jones-Hughes, T., Hoyle M., Briscoe, S., Coelho, H., Long, L., Medina-Lara, A., Mujica-Mota, R., Napier, M., Rudin, C., Scatchard, K., Hyde, C. (2014) “The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model.”
  • Hoyle M., Snowsill, T., Haasova, M., Cooper, C., Rudin, C. (2013) “Bosutinib for previously treated chronic myeloid leukaemia: A Single Technology Appraisal. Critique of submission from Pfizer”.
  • Hoyle M., Pavey, T., Ciani, O., Crathorne, L., Jones-Hughes, T., Cooper, C., Osipenko, L., Venkatachalam, M., Rudin, C., Ukoumunne, O., Garside, R., Anderson, R. (2011) "Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses".
  • Hoyle M., Crathorne, L., Peters, J., Jones-Hughes, T., Cooper, C., Napier, M., Hyde C. (2011) "The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with nonoxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model".
  • Hoyle M., Crathorne, L., Jones-Hughes, T., Stein K. (2010) "Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate: a critique of the submission from Napp"
  • Bond, M., Rogers, G., Peters, J., Anderson, R., Hoyle M., Miners, A., Moxham, T., Davis, S., Thokala, P., Jeffreys, M., Hyde, C. (2012) “The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of mild to moderate Alzheimer’s disease (review of TA111): a systematic review and economic model”.
  • Hoyle, M., Crathorne, L., Moxham, T., Garside, R., Hyde, C. (2011) “Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK”.
  • Thompson-Coon, J., Rogers, G., Hoyle, M., Pitt, M., Rogers, G., Moxham, T., Liu, Z., Stein, K. (2012) “Dasatinib and Nilotinib for imatinib-resistant or intolerant chronic myeloid leukaemia: A systematic review and economic evaluation”.
  • Bond, M., Hoyle, M., Moxham, T., Napier, M., Anderson, R. (2009) “Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer”.
  • Hoyle, M., Rogers, G., Garside, R., Moxham, T., Stein, K. (2008) “The clinical- and cost effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene”.
  • Garside, R., Green, C., Hoyle, M., Taylor, R., Price, A., Stein, K. (2007) “The effectiveness and cost effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen”.
  • Thompson-Coon, J., Hoyle, M., Green, C., Liu, Z., Welch, K., Moxham, T., Stein, K. (2008) “Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation”.
  • Bond, M., Mealing, S., Anderson, R. Elston, J., Weiner, G., Taylor, R., Hoyle, M., Liu, Z., Price, A., Stein, K. (2009) “The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model”.
  • Bond, M., Pitt, M., Akoh, J., Moxham, T., Hoyle, M., Anderson, R. (2009) “The effectiveness and cost effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model”.

NIHR HTA

  • Jones-Hughes T., Snowsill T., Haasova M., Coelho H, Crathorne L., Cooper C., Mujica-Mota R., Peters J.,  Varley-Campbell J., Huxley N., Moore J., Allwood M., Lowe J., Hyde C., Hoyle M., Bond M., Anderson R. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess 2016;20 (62)
  • Huxley M., Crathorne L., Varley-Campbell J., Tikhonova I., Snowsill T., Briscoe S., Peters J., Bond  M., Napier M., Hoyle M. (2015) “Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer. Health Technology Assessment, In press.
  • Crathorne, L., Huxley, N., Haasova, M., Snowsill, T., Jones-Hughes, T., Hoyle, M., Briscoe,  S., Coelho, H., Long, L., Medina-Lara, A., Mujica-Mota, R., Napier, M., Rudin, C., Scatchard, K., Hyde, C. (2016) “The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model.”, Health Technology Assessment volume 20, number 13.
  • Snowsill, T., Huxley, N., Hoyle, M., Jones-Hughes, T., Coelho, H., Cooper, C., Frayling, I., Hyde, C. (2014) “A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome”, Health Technology Assessment, 18:58.
  • Pavel T., Hoyle M., Ciani O., Crathorne L., Jones-Hughes T., Cooper C., Osipenko L., Venkatachalam M., Rudin C., Ukoumunne O., Garside R., Anderson R. “Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses”, Health Technology Assessment, 2012, 16; 42.
  • Hoyle, M., Crathorne, L., Peters, J., Jones-Hughes, T., Cooper, C., Napier, M., Hyde C. "The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non- oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model", Health Technol. Assess. 2013, 17(14)
  • Bond, M., Rogers, G., Peters, J., Anderson, R., Hoyle, M., Miners, A., Moxham, T., Davis, S., Thokala, P., Jeffreys, M., Hyde, C. (2012) “The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of mild to moderate Alzheimer’s disease (review of TA111): a systematic review and economic model”, Health Technology Assessment, 16(21).
  • Rogers, G., Hoyle, M., Thompson-Coon, J., Pitt, M., Moxham, T., Liu, Z., Stein, K. (2012) “Dasatinib and Nilotinib for imatinib-resistant or intolerant chronic myeloid leukaemia: A systematic review and economic evaluation”, Health Technology Assessment, 16; 22.
  • Bond, M., Hoyle, M., Moxham, T., Napier, M., Anderson, R. (2009) “Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer”, Health Technol. Assess. 13: Suppl. 2, p69-74.
  • Thompson-Coon, J., Hoyle, M., Green, C., Liu, Z., Welch, K., Moxham, T., Stein, K. (2010) “Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation”, Health Technol. Assess. 14(2).
  • Bond, M., Mealing, S., Anderson, R. Elston, J., Weiner, G., Taylor, R., Hoyle, M., Liu, Z., Price, A., Stein, K. (2009) “The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model”, Health Technol. Assess., 13(44).
  • Bond, M., Pitt, M., Akoh, J., Moxham, T., Hoyle, M., Anderson, R. (2009) “The effectiveness and cost effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model”, Health Technol. Assess. 13(38)

Funding and grants

  • 2017-9 with option to extend to 2020. Collaborator on the Decision Support Unit (DSU) contract with NICE to develop Technical Support Documents to advice methodology for HTA. NICE £160,000 p.a., but as collaborator status, no income to University of Exeter.
  • 2015-7 “Brazil-UK collaboration in Health Technology Assessment of diagnostic strategies for infectious diseases.” Hyde, C., Anderson, R., Crathorne, L., Hoyle, M ., et al. To strengthen and maintain an enduring and productive scientific partnership between the University of Exeter and the Oswaldo Cruz Foundation (Fiocruz), Brazil. Newton Fund. The total value is £49,000, from the RCUK Newton Fund.
  • 2016-21 Technology Assessment Report (TAR) contract. To perform HTAs mostly for NICE, but also for NIHR and National Screening Committee. Department of Health. Total value is £3.5 million.
  • 2011-6 Technology Assessment Report (TAR) contract. To perform HTAs mostly for NICE, but also for NIHR and National Screening Committee. Department of Health The total value of the grant was £3.5 million.

Presentations

  • Survival analysis, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 19th Annual Congress, Vienna, Nov 2016.
  • “Consultation on NICE’s Abbreviated Technology Appraisal (ATA) Process”, London, NICE. 2016
  • Incorporating environmental impacts into health economics and decision making: What method could national organisations incorporate now?, London, NHS Sustainable Development Unit.
  • InterTASC (association of UK TAR groups) meeting on survival analysis, University of York. Oct 2014
  • Survival analysis, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 16th Annual Congress, Dublin. Nov 2013
  • Invited participant “QALY weightings for Value-Based Pricing: Technical Workshop”, Dept. Health, Manchester. Nov 2012
  • Economic Modelling, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 15th Annual Congress, Berlin, Nov 2012
  • Methodological Advances for Modelling Cost effectiveness of Cancer Medicines, Office of Health Economics, London, April 2012
  • Adjusting for Treatment Switching in RCTs, MRC, London. Feb 2012
  • Measuring and valuing health, workshop to develop NICE’s 2013 Methods Guidance. Nov 2011
  • QALY weighting”, to develop NICE’s 2013 Methods Guidance, Dec 2011
  • 3rd Annual Oncology Market & Patient Access conference, Barcelona. Feb 2011
  • Invited speakerand panel member Office for Health Economics (OHE), Pharmaceutical, Nov 2008

Awards

  • ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes, 2011

Recreation of individual patient data

The method of Hoyle & Henley (2011): Improved curve fits to summary survival data: application to economic evaluation of health technologies.  BMC Medical Research Methodology, 11:139 is given here.  A spreadsheet to implement the method is given here.  It can be used to recreate individual patient data from summary survival data.

Back to the top of this page